lactic acid has been researched along with Infections, Chlamydia in 4 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Edwards, VL | 1 |
| Smith, SB | 1 |
| McComb, EJ | 1 |
| Tamarelle, J | 1 |
| Ma, B | 1 |
| Humphrys, MS | 1 |
| Gajer, P | 1 |
| Gwilliam, K | 1 |
| Schaefer, AM | 1 |
| Lai, SK | 1 |
| Terplan, M | 1 |
| Mark, KS | 1 |
| Brotman, RM | 1 |
| Forney, LJ | 1 |
| Bavoil, PM | 1 |
| Ravel, J | 1 |
| Chappell, BT | 1 |
| Mena, LA | 1 |
| Maximos, B | 1 |
| Mollan, S | 1 |
| Culwell, K | 1 |
| Howard, B | 1 |
| Bharatwaj, B | 1 |
| Wu, L | 1 |
| Whittum-Hudson, JA | 2 |
| da Rocha, SR | 1 |
| Toti, US | 1 |
| Guru, BR | 1 |
| Hali, M | 1 |
| McPharlin, CM | 1 |
| Wykes, SM | 1 |
| Panyam, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2B Double-blind Placebo-controlled Efficacy Trial of EVO100 (Previously Known as Amphora ® Gel) for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection[NCT03107377] | Phase 2/Phase 3 | 860 participants (Actual) | Interventional | 2017-11-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Summary of Coital Events during treatment (NCT03107377)
Timeframe: 16 weeks
| Intervention | Coital Events (Mean) |
|---|---|
| EVO100 | 15.7 |
| Placebo | 16.3 |
Summary of number of applicators used via eDiary (NCT03107377)
Timeframe: 16 weeks
| Intervention | Number of Applicators (Mean) |
|---|---|
| EVO100 | 13.0 |
| Placebo | 13.5 |
Study product adherence (NCT03107377)
Timeframe: 16 weeks
| Intervention | % of sex acts where study product used (Mean) |
|---|---|
| EVO100 | 78.9 |
| Placebo | 78.3 |
Proportion of subjects who experience urogenital CT infection during the study intervention period (incident infection of CT). (NCT03107377)
Timeframe: 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| EVO100 | 14 |
| Placebo | 28 |
Proportion of subjects who experience urogenital GC infection during the study intervention period (incident infection of GC). (NCT03107377)
Timeframe: 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| EVO100 | 2 |
| Placebo | 9 |
1 trial available for lactic acid and Infections, Chlamydia
| Article | Year |
|---|---|
EVO100 prevents chlamydia and gonorrhea in women at high risk of infection.
Topics: Administration, Intravaginal; Adult; Anti-Infective Agents; Chlamydia Infections; Citric Acid; Drug | 2021 |
3 other studies available for lactic acid and Infections, Chlamydia
| Article | Year |
|---|---|
The Cervicovaginal Microbiota-Host Interaction Modulates Chlamydia trachomatis Infection.
Topics: Cell Movement; Cell Proliferation; Cervix Uteri; Chlamydia Infections; Chlamydia trachomatis; Female | 2019 |
The potential for the noninvasive delivery of polymeric nanocarriers using propellant-based inhalers in the treatment of Chlamydial respiratory infections.
Topics: Aerosol Propellants; Aerosols; Anti-Bacterial Agents; Cell Line; Chlamydia; Chlamydia Infections; Co | 2010 |
Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles.
Topics: Anti-Bacterial Agents; Azithromycin; Cell Line; Chemistry, Pharmaceutical; Chlamydia Infections; Chl | 2011 |